Drug intelligence / Profile preview

ketoconazole + sufentanil

Development stage
Phase 1
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Oral, Topical, Sublingual, Intravenous, Epidural, Intrathecal
01

Overview

Ketoconazole + sufentanil is a combination of two pharmaceutical agents with distinct mechanisms of action. Ketoconazole is an imidazole antifungal agent that inhibits fungal ergosterol synthesis by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase. It is also a potent inhibitor of CYP3A4 in humans, which can significantly increase the systemic exposure to drugs metabolized by this enzyme, such as sufentanil. Sufentanil is a synthetic opioid analgesic and anesthetic that acts as a highly selective full agonist at μ-opioid receptors in the central nervous system, producing profound analgesia and sedation. The combination may be clinically relevant due to pharmacokinetic interactions; co-administration with ketoconazole can increase plasma concentrations of sufentanil by inhibiting its metabolism via CYP3A4[6]. This interaction increases both efficacy and risk for adverse effects such as respiratory depression.

Brand names
Zalviso
02

Targets

CYP51A1 (Sterol 14α-demethylase)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ketoconazole + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketoconazole + sufentanil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call